

WHO GUIDELINES FOR THE

Treatment of *Treponema pallidum* (syphilis)



WHO GUIDELINES FOR THE

Treatment of *Treponema pallidum* (syphilis)



World Health
Organization

WHO Library Cataloguing-in-Publication Data

WHO guidelines for the treatment of *Treponema pallidum* (syphilis).

Contents: Web annex D: Evidence profiles and evidence-to-decision frameworks - Web annex E: Systematic reviews for syphilis guidelines - Web annex F: Summary of conflicts of interest

1.Syphilis – drug therapy. 2.*Treponema pallidum*. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization.

ISBN 978 92 4 154980 6 (NLM classification: WC 170)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

CONTENTS

Acknowledgements	iii
Abbreviations and acronyms	iv
Executive summary	1
Overview of the guidelines for the prevention, treatment and management of STIs	6
STI epidemiology and burden	6
Why new guidelines for the prevention, treatment and management of STIs?	6
Approach to the revision of STI guidelines	8
References	9
WHO guidelines for the treatment of <i>Treponema pallidum</i> (syphilis)	10
1. Introduction	10
1.1 Epidemiology, burden and clinical considerations	10
Clinical presentation	10
Laboratory diagnosis	11
1.2 Rationale for new recommendations	13
1.3 Objectives	14
1.4 Target audience	14
1.5 Structure of the guidelines	14
2. Methods	15
2.1 Guideline Development Group (GDG)	15
2.2 Questions and outcomes	15
2.3 Reviews of the evidence	15
2.4 Making recommendations	16
2.5 Management of conflicts of interest	17
3. Dissemination, updating and implementation of the guidelines	18
3.1 Dissemination	18
3.2 Updating the STI guidelines and user feedback	18
3.3 Implementation of the WHO guidelines for the treatment of <i>T. pallidum</i> (syphilis)	18
Adaptation, implementation and monitoring	18
Identifying and procuring STI medicines	19
4. Recommendations for treatment of syphilis	20
4.1 Early syphilis	20
Recommendation 1	20
Recommendation 2	20
Recommendation 3	21
Recommendation 4	21
4.2 Late syphilis	22
Recommendation 5	22
Recommendation 6	22
Recommendation 7	22
Recommendation 8	22

CONTENTS (CONTINUED)

4.3 Congenital syphilis	23
Recommendation 9	23
Recommendation 10	23
5. Research implications	25
References	26
Annex A: STI guideline development teams	27
Annex B: Detailed methods for guidelines development	36
Questions and outcomes	36
Review of the evidence	42
Applying the GRADE approach to making the recommendations	44
Annex C: Lists of references for reviewed evidence	45
Recommendation 1 and 2	45
Recommendation 3 and 4	46
Recommendation 5 and 6	47
Recommendation 7 and 8	48
Recommendation 9	48
Recommendation 10	48

Web annexes available at:

www.who.int/reproductivehealth/publications/rtis/syphilis-treatment-guidelines/en/

Web annex D: Evidence profiles and evidence-to-decision frameworks

Web annex E: Systematic reviews for syphilis guidelines

Web annex F: Summary of conflicts of interest

ACKNOWLEDGEMENTS

The Department of Reproductive Health and Research at the World Health Organization (WHO) would like to thank the members of the STI Guideline Development Group for their consistent availability and commitment to making these guidelines possible. The Department is also grateful to the STI External Review Group for peer reviewing these guidelines, and appreciates the contribution of the WHO Steering Committee. The names of the members of each group are listed below, with full details provided in Annex A.

Special thanks to Dr Nancy Santesso, the guideline methodologist who also led the systematic review process, for her hard work and firm commitment of the guideline development process. We also thank the members of the Systematic Review Team from McMaster University.

We appreciate the overall support of the WHO Guideline Review Committee Secretariat during the guideline development process, with grateful thanks to Dr Susan Norris.

We thank Theresa Ryle for the administrative support, and 400 Communication for assistance with the guideline design and layout. This guideline document was edited by Ms Jane Patten, of Green Ink, United Kingdom.

Dr Teodora Wi led the guideline development process and Dr Nathalie Broutet co-led the process under the supervision of Dr James Kiarie and leadership of Dr Ian Askew. Lee Sharkey provided support during the guideline development process.

FUNDING

The preparation and printing of the guidelines were funded exclusively by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). No external source of funding was solicited or utilized.

CONTRIBUTORS TO WHO GUIDELINES ON THE TREATMENT OF *TREPONEMA PALLIDUM*

STI Guideline Development Group (GDG):

Chairpersons: Judith Wasserheit, Holger Schünemann and Patricia Garcia

Members: Yaw (Sax) Adu-Sarkodie, Andrew Amato, Gail Bolan, John Changalucha, Xiang-Sheng Chen, Harrel Chesson, Craig Cohen, Francisco Garcia, Suzanne Garland, Sarah Hawkes, Mary Higgins, King Holmes, Jeffrey Klausner, David Lewis, Nicola Low, David Mabey, Angelica Espinosa Miranda, Nelly Mugo, Saiqa Mullick, Francis Ndowa, Joel Palefsky, Keith Radcliffe, Ulugbek Sabirov, Judith Stephenson, Richard Steen, Magnus Unemo, Bea Vuylsteke, Anna Wald, Thomas Wong and Kimberly A. Workowski

STI GDG working group for syphilis: Gail Bolan, John Changalucha, Xiang-Sheng Chen, Patricia Garcia, Suzanne Garland, Antonio Gerbase, Jeffrey Klausner, Ornella Lincetto, David Mabey, Saiqa Mullick, Joel Palefsky, Ulugbek Sabirov, Richard Steen

STI External Review Group: Laith Abu-Raddad, Chris Akolo, Adele Benaken-Schwartz, Mircea Betiu, Anupong Chitwarakorn, Carolyn Deal, Margaret Gale-Rowe, William M. Geisler, Mary Kamb, Amina El Kettani, Mizan Kiro, Ahmed Latif, Philippe Mayaud, David McCartney, Ali M. Mir, Nuriye Ortayli, Pablo Sanchez, Khantanouvieng Sayabounthavong and Aman Kumar Singh

WHO Steering Committee:

WHO regional offices: Massimo Ghidinelli, Hamida Khattabi, Lali Khotenashvili, Ornella Lincetto, Ying-Ru Lo, Frank Lule and Razia Pendse

WHO headquarters: Moazzam Ali, Avni Amin, Rachel Baggaley, Venkatraman Chandra-Mouli, Jane Ferguson, Mario Festin, Mary Lyn Gaffield, Antonio Gerbase, Sami Gottlieb, Frances McConville, Lori Newman, Annette Mwansa Nkowane, Anita Sands, Igor Toskin and Marco Vitoria

WHO STI Secretariat: Ian Askew, Teodora Elvira Wi (lead, development of the guidelines), Nathalie Broutet (co-lead, development of the guidelines), James Kiarie and Lee Sharkey

Systematic Review Team: Nancy Santesso (lead), Housne Begum, Janna-Lina Kerth, Gian Paolo Morgano, Kristie Poole, John Riva, Nicole Schwab, Matthew Ventresca, Yuan Zhang and Andrew Zikic (members)

Methodologist: Nancy Santesso.

ABBREVIATIONS AND ACRONYMS

AIDS	acquired immune deficiency syndrome	NAAT	nucleic acid amplification test
AMR	antimicrobial resistance	PCR	polymerase chain reaction
CI	confidence interval	PICO	population, intervention, comparator, outcome
DFA	direct fluorescent antibody	PMTCT	prevention of mother-to-child transmission
DNA	deoxyribonucleic acid	RDT	rapid diagnostic tests
DOI	declaration of interests	RPR	rapid plasma reagin
FTA-ABS	fluorescent treponemal antibody absorbed	STI	sexually transmitted infection
GDG	Guideline Development Group	TPHA	<i>Treponema pallidum</i> haemagglutination assay
GRADE	Grading of Recommendations Assessment, Development and Evaluation	TPPA	<i>Treponema pallidum</i> particle agglutination assay
GUD	genital ulcer disease	TRUST	Toluidine Red Unheated Serum Test
HIV	human immunodeficiency virus	VDRL	Venereal Diseases Research Laboratory
HPV	human papillomavirus		
HSV	herpes simplex virus		
HSV-1	herpes simplex virus type 1		
HSV-2	herpes simplex virus type 2		

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27167

